DelveInsight’s, “Pneumococcal Infections Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pneumococcal Infections pipeline landscape. It covers the Pneumococcal Infections pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pneumococcal Infections pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances in Pneumococcal Infections Treatment Drugs @ Pneumococcal Infections Pipeline Drugs Report
Key Takeaways from the Pneumococcal Infections Pipeline Report
- In January 2026- Shanghai Reinovax Biologics Co. Ltd announced a Phase II clinical trial of the 24-valent pneumococcal polysaccharide conjugate vaccine (RZ700) will be carried out in infants and young children aged 2 months (minimum 6 weeks) to 71 months. The purpose of this study is to evaluate the immunogenicity and safety of the 24-valent pneumococcal polysaccharide conjugate vaccine.
- In January 2026- Sinovac Life Sciences Co., Ltd. conducted a Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13.
- DelveInsight’s Pneumococcal Infections Pipeline analysis depicts a robust space with 15+ Pneumococcal Infections companies working to develop 20+ pipeline treatment therapies.
- The leading Pneumococcal Infections Companies such as GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte and others.
- Promising Pneumococcal Infections Pipeline Therapies such as V116, PCV15, PPSV23, Sinovac PCV24, 20vPCV, Sinovac PCV13, PNEUMOVAX™23 and others.
Find out more about Pneumococcal Infections Therapeutics Assessment Report @ Pneumococcal Infections Preclinical and Discovery Stage Products
The Pneumococcal Infections Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Pneumococcal Infections Pipeline Report also highlights the unmet needs with respect to the Pneumococcal Infections.
Pneumococcal Infections Overview
Pneumococcal infections are bacterial infections caused by Streptococcus pneumoniae (pneumococcus), a pathogen that commonly colonizes the human upper respiratory tract but can lead to serious illness when it invades other parts of the body.
Pneumococcal Infections Emerging Drugs
- ASP3772: Affinivax
ASP3772 is designed to elicit both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. ASP3772 includes 24 pneumococcal polysaccharides, as well as two conserved pneumococcal proteins. The results from the Phase II clinical trial demonstrated that ASP3772 was well tolerated. ASP3772 also exhibited an antibody response to each of the 24 polysaccharides, as well as an additional antibody response to the conserved pneumococcal proteins. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ASP3772 for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes included in ASP3772 in adults aged 50 years and older. The FDA decision is informed by the results of the Phase 2 clinical data. The FDA’s Breakthrough Therapy process is designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition.
Explore the dynamic world of drug development with our latest Pneumococcal Infections Pipeline Insights report! Download Now! @ Pneumococcal Infections Treatment Drugs
The Pneumococcal Infections pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Pneumococcal Infections with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pneumococcal Infections Treatment.
- Pneumococcal Infections Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Pneumococcal Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pneumococcal Infections market.
Pneumococcal Infections Companies
GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte and others.
Pneumococcal Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intranasal
- Intrathecal
- Intravenous
- Oral
- Oral/Intravenous
- Parenteral
- Subcutaneous
- Subcutaneous/Intramuscular
- Transdermal
Pneumococcal Infections Products have been categorized under various Molecule types such as
- Antisense oligonucleotide
- Gene therapy
- Hormones
- Neuropeptides
- Oligonucleotides
- Small Molecule
- Triglyceride
Learn more about the emerging Pneumococcal Infections Pipeline Therapies @ Pneumococcal Infections Clinical Trials Assessment
Scope of the Pneumococcal Infections Pipeline Report
- Coverage- Global
- Pneumococcal Infections Companies- GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte and others.
- Pneumococcal Infections Pipeline Therapies- V116, PCV15, PPSV23, Sinovac PCV24, 20vPCV, Sinovac PCV13, PNEUMOVAX™23 and others.
- Pneumococcal Infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Pneumococcal Infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which Pneumococcal Infections Companies are leading the way in drug discovery? Download now to stay at the forefront of pharmaceutical innovation!” @ Pneumococcal Infections Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Pneumococcal infections: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Pneumococcal infections– DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase III)
- Ceftobiprole medocaril: Basilea Pharmaceutica
- Mid Stage Products (Phase II)
- ASP3772: Affinivax
- Early Stage Products (Phase I/II)
- Pneumococcal vaccine conjugate 10-valent: Panacea Biotech
- Early Stage Products (Phase I)
- Pneumococcal conjugate vaccine: EuBiologics
- Preclinical Stage Products
- VAX XP: Vaxcyte
- Inactive Products
- Pneumococcal infections Key Companies
- Pneumococcal infections Key Products
- Pneumococcal infections- Unmet Needs
- Pneumococcal infections- Market Drivers and Barriers
- Pneumococcal infections- Future Perspectives and Conclusion
- Pneumococcal infections Analyst Views
- Pneumococcal infections Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
